NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update
- Successful transformation to global biotech platform with two mid-stage potential best-in-class/first-in-class programs, givastomig and VIS-101, with compelling proof-of-concept data
- Givastomig, a potential best-in-class/first-in-class Claudin 18.2-directed bispecific antibody for gastric cancer, has shown robust and durable responses with broad CLDN18.2 activity, favorable safety, as well as potential eligibility for FDA’s Accelerated Approval Pathway with potential initiation of a registrational Phase 3 trial as early as Q4 2026
- VIS-101, a potential best-in-class VEGF-A X ANG-2 inhibitor for wet-AMD, produced rapid, robust and durable responses in treatment naïve wet-AMD patients, and is poised to begin Phase 2b studies in H2 2026
- Expanded, world-class Board of Directors and Executive Team in place to drive growth
- Strong financial position with
$210.8 million of cash as ofDecember 31, 2025 , expected to support operations through 2028
“2025 was a consequential year for NovaBridge, with our successful transformation to a global biotech platform. The accelerated momentum that we have experienced over the last quarter – marked by compelling proof-of-concept data for our two potential class-leading, blockbuster product candidates, givastomig and VIS-101 -- serves as strong validation of our strategy,” said
“Compelling clinical results from the last quarter have reinforced the class-leading potential for givastomig and VIS-101 and meaningfully de-risked their clinical paths forward. For givastomig, the FDA confirmed potential eligibility for an Accelerated Approval pathway at a productive Type B meeting, following robust potential best-in-class Phase 1b efficacy and favorable overall tolerability results. At the same time, VIS-101 continues to advance in wet AMD following its successful Phase 2a readout showing rapid, robust, durable and potential best-in-class responses,” said
Pipeline Overview and Potential Upcoming Milestones
NovaBridge’s late-stage potential class-leading pipeline is led by givastomig for the treatment of gastric cancer, and VIS-101 for the care of wet AMD:
Givastomig Update
Givastomig, a bispecific CLDN18.2 X 4-1BB antibody targeting Claudin 18.2-positive (CLDN 18.2+) tumor cells, is being developed for the treatment of first line (1L) metastatic gastric cancer. Currently, there are approximately 180,0001 patients diagnosed with 1L gastric cancer in the US/EU5 and
NovaBridge reported positive Phase 1b dose expansion data in
- Robust efficacy, with 75% objective response rate (n=52 evaluable subjects, 50/50 at 8 mg/kg or 12 mg/kg)
- Responses observed across a range of PD-L1 and CLDN18.2 expression levels
- Durable responses with 16.9-month median progression free survival (n=53 evaluable subjects, 50/50 at 8 mg/kg or 12 mg/kg)
- Good overall tolerability in combination with immunochemotherapy, without dose dependent toxicity
Givastomig has broad potential in gastric cancer and other CLDN18.2+ tumors such as pancreatic ductal adenocarcinoma and biliary tract cancer.
In
Upcoming Givastomig Milestones:
- 2026: Medical meeting presentation of Phase 1b combination gastric cancer data
- YE 2026: Potential to begin Accelerated Approval Pathway Phase 3 study as early as YE 2026
VIS-101 Update and Upcoming Milestones
VIS-101, a dual purpose-designed VEGF-A X ANG-2 inhibitor, is being developed for wet AMD, estimated to affect more than 20 million people globally4.
Visara reported positive Phase 2a data in
- Good safety and tolerability
- Rapid, robust and durable treatment responses
- Mean BCVA >10 ETDRS letters
- Mean CST 100 - 150 um
- Potentially best-in-class durability with:
- ~two thirds of patients retreatment free at four months
- ~half of patients retreatment free at six months
VIS-101 has broad potential in retinal vascular diseases including wet AMD, diabetic macular edema (DME) and retinal vein occlusion (RVO), which, together, affect more than 57 million people globally4.
Upcoming VIS-101 Milestones:
- H2 2026: Initiate Phase 2b program in wet-AMD
- 2027: Initiate global Phase 3 program
2025 Selected Corporate Development Highlights:
Executive Appointments:
Emmett T. Cunningham , Jr., MD, PhD, MPH, Vice-Chairman of the NovaBridge Board of Directors, and Founder and Executive Chairman, VisaraKyler Lei , MSc, Chief Financial Officer of NovaBridge- Expansion of the NovaBridge Board of Directors, with the appointments of
Robert Lenz , MD, PhD;Xin Liu , MEng, MFin;Sean Cao , PhD, MBA;Emmett T. Cunningham , Jr., MD, PhD, MPH; and Ian Woo, MA, MBA, with:- Appointments of
Dr. Lenz (Chairman),Dr. Cunningham , andDr. Cao to the NovaBridgeResearch and Development Committee - Appointment of
Ken Takeshita , MD to the NovaBridgeScientific Advisory Board
- Appointments of
- Buildout of the Visara Executive Team with the appointment of
Cadmus Rich , MD, MBA, as Chief Medical Officer, and formation of the:Visara Scientific Advisory Board , with the appointment ofCarlos Quezada-Ruiz , MD, FASRS (Chairman)
Strategic Business Development Transactions:
- NovaBridge: Strategic transformation to a global biotech platform to advance high-value therapeutic assets through its “hub-and-spoke” model
Bridge Health : Acquisition of rights and patent filings related to multiple bispecific antibodies and antibody drug conjugates, based on the parental antibody used in givastomig-related antibodies- Visara, Inc: Formation of NovaBridge’s first “spoke”, executed through a series of collaborative agreements, including completion of a Series A Financing and partnerships with AskGene and Everest Medicines, related to worldwide rights for VIS-101 outside of Greater China and certain other countries in
Asia
Full Year 2025 Financial Results
Cash Position
As of
Shares Outstanding
As of December 31, 2025, the Company had 265,377,891 ordinary shares issued and outstanding, representing the equivalent of 115,381,692 ADSs, assuming the conversion of all ordinary shares into ADSs.
Research & Development Expenses
Research and development (R&D) expenses were
Administrative Expenses
Administrative expenses were
Interest Income
Interest income was
Other Income (Expenses), Net
Other expenses, net were
Equity in Loss of Affiliates
Equity in loss of affiliates was zero for the year ended
Net Loss from Continuing Operations
Net loss from continuing operations was
Gain (Loss) from Discontinued Operations
Net loss from discontinued operations was zero for the year ended
Net Loss Attributable to Redeemable Noncontrolling Interests
Net loss attributable to redeemable Noncontrolling Interests (“NCI”) was
Net Loss attributable to NovaBridge
Net loss attributable to NovaBridge was
About Givastomig
Givastomig (TJ033721 / ABL111) is a bispecific CLDN 18.2 X 4-1BB antibody targeting Claudin 18.2 (CLDN18.2)-positive (CLDN 18.2+) tumor cells. It conditionally activates T cells through the 4-1BB signaling pathway in the tumor microenvironment where CLDN18.2 is expressed. Givastomig is being developed for potential treatment of gastric cancer and other Claudin 18.2+ gastrointestinal malignancies. In Phase 1 trials, givastomig has shown promising anti-tumor activity attributable to a potential synergistic effect of the proximal interaction between CLDN18.2 on tumor cells and 4-1BB on T cells in the tumor microenvironment, while minimizing toxicities commonly seen with other 4-1BB agents.
Givastomig is being jointly developed through a global partnership with ABL Bio, in which NovaBridge is the lead party and shares worldwide rights, excluding Greater China and
About VIS-101
VIS-101 (also known as ASKG712 or AM712), purpose-designed to be best-in-class, is a dual VEGF-A X ANG-2 inhibitor in development for the treatment of retinal vascular diseases, such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO), which, together, affect more than 57 million people globally4. VIS-101’s bispecific, tetravalent design format provides more binding sites and increased VEGF-A and ANG-2 affinity, for rapid, robust and class-leading durable responses. VIS-101 has completed initial safety and dose-escalation studies in both the US and China and a randomized, dose-ranging 2a study in China (NCT05456828). VIS-101 is expected to advance to a dose-determining Phase 2b study in 2026, with initiation of the global Phase 3 program in 2027.
NovaBridge is the majority shareholder of Visara, and Visara controls global rights to VIS-101 outside of greater
Source information:
- Markets include
U.S. , five E.U. countries, andJapan in 2025 based on Data Monitor Biomed Tracker, based on 1L treatment - HER2-negative status of 78%. Van Cutsem E, Bang YJ,
Feng-Yi F , et al. HER-2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 2015;18(3):476-84 - CLDN18.2 positive status of ~70%.
Kohei Shitara , et al, 2023 ASCO Annual Meeting (June 2-6 ), poster #4035 - Invest Ophthalmol Vis Sci. 2021 Nov 24; 62 (14): 26. doi: 10.1167/iovs.62.14.26
About NovaBridge
NovaBridge is a global biotechnology platform company committed to accelerating access to innovative medicines. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. By bridging science, strategy, and execution, NovaBridge enables transformative therapies to progress rapidly from discovery toward patients in need.
The Company’s differentiated pipeline is led by givastomig, a potential first-in-class and best-in-class, Claudin 18.2 X 4-1BB bispecific antibody, and VIS-101, purpose-designed to be a best-in-class dual VEGF-A X ANG-2 inhibitor.
Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. The product candidate is being evaluated in a global, randomized Phase 2 study, following the recent announcement of positive topline results from a Phase 1b, multi-center, open label study in first line gastric cancer. The Company is also collaborating with its partner, ABL Bio, for the development of ragistomig, a bispecific antibody integrating PD-L1 as a tumor engager and 4-1BB as a conditional T cell activator, in solid tumors. Additionally, NovaBridge owns worldwide rights outside of
VIS-101 targets VEGF-A and ANG-2 to provide more rapid, robust and durable treatment responses for patients with retinal vascular diseases including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. VIS-101 has completed a randomized, dose-ranging Phase 2a study for wet AMD and expects to initiate a dose-determining Phase 2b study in H2 2026. NovaBridge is the majority shareholder of
For more information, please visit www.novabridge.com and follow us on LinkedIn.
Forward Looking Statements
This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the
I-Mab Investor & Media Contacts
PJ Kelleher
+1-617-430-7579
pkelleher@lifesciadvisors.com
IR@imabbio.com
| Consolidated Balance Sheets |
||||||||
| As of |
||||||||
| (All amounts in thousands, except for share data, unless otherwise noted) |
||||||||
| As of |
||||||||
| 2025 |
2024 |
|||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 210,632 | $ | 68,263 | ||||
| Short-term investments | 210 | 105,135 | ||||||
| Prepayments and other receivables | 6,678 | 3,295 | ||||||
| Total current assets | 217,520 | 176,693 | ||||||
| Property, equipment and software | 140 | 201 | ||||||
| Operating lease right-of-use assets | 2,809 | 3,597 | ||||||
| Investments at fair value, available-for-sale debt securities (amortized cost of |
— | 30,824 | ||||||
| Investments at fair value, equity securities | 37,241 | — | ||||||
| Other non-current assets | 2,812 | 1,365 | ||||||
| Total assets | $ | 260,522 | $ | 212,680 | ||||
| Liabilities and shareholders’ equity | ||||||||
| Current liabilities | ||||||||
| Accruals and other payables (including amounts with related parties of respectively) |
$ | 16,823 | $ | 7,532 | ||||
| Other current liabilities | 9,180 | 106 | ||||||
| Operating lease liabilities, current | 891 | 816 | ||||||
| Total current liabilities | 26,894 | 8,454 | ||||||
| Operating lease liabilities, non-current | 2,176 | 3,066 | ||||||
| Other non-current liabilities | 511 | — | ||||||
| Total liabilities | 29,581 | 11,520 | ||||||
| Shareholders’ equity | ||||||||
| Ordinary shares ( outstanding as of |
27 | 19 | ||||||
| (5,042 | ) | (6,225 | ) | |||||
| Additional paid-in capital | 1,526,718 | 1,460,021 | ||||||
| Accumulated other comprehensive income | 41,546 | 33,384 | ||||||
| Accumulated deficit | (1,332,308 | ) | (1,286,039 | ) | ||||
| Total shareholders’ equity | 230,941 | 201,160 | ||||||
| Total liabilities and shareholders’ equity | $ | 260,522 | $ | 212,680 | ||||
| Consolidated Statements of Comprehensive Loss |
||||||||||||
| For the Years Ended |
||||||||||||
| (All amounts in thousands, except for share and per share data, unless otherwise noted) |
||||||||||||
| Year Ended |
||||||||||||
| 2025 |
2024 |
2023 |
||||||||||
| Revenues | ||||||||||||
| Licensing and collaboration revenue | $ | — | $ | — | $ | 632 | ||||||
| Total revenues | — | — | 632 | |||||||||
| Expenses | ||||||||||||
| Research and development expenses (including amounts with related parties of |
(62,905 | ) | (21,770 | ) | (21,448 | ) | ||||||
| Administrative expenses (including amounts with related parties of |
(31,364 | ) | (29,656 | ) | (28,160 | ) | ||||||
| Impairment of goodwill | — | — | (23,041 | ) | ||||||||
| Total expenses | (94,269 | ) | (51,426 | ) | (72,649 | ) | ||||||
| Loss from operations | (94,269 | ) | (51,426 | ) | (72,017 | ) | ||||||
| Interest income | 7,611 | 7,486 | 9,294 | |||||||||
| Other expenses, net | (1,682 | ) | (4,718 | ) | (8,090 | ) | ||||||
| Equity in loss of affiliates | — | (1,038 | ) | (11,404 | ) | |||||||
| Loss from continuing operations before income tax expense | (88,340 | ) | (49,696 | ) | (82,217 | ) | ||||||
| Income tax expense | — | — | — | |||||||||
| Loss from continuing operations | $ | (88,340 | ) | $ | (49,696 | ) | $ | (82,217 | ) | |||
| Discontinued operations: | ||||||||||||
| Loss from operations of discontinued operations | $ | — | $ | (6,898 | ) | $ | (125,512 | ) | ||||
| Income tax expense | — | — | — | |||||||||
| Gain on sale of discontinued operations | — | 34,364 | — | |||||||||
| Gain (loss) from discontinued operations | $ | — | $ | 27,466 | $ | (125,512 | ) | |||||
| Net loss | $ | (88,340 | ) | $ | (22,230 | ) | $ | (207,729 | ) | |||
| Net loss attributable to redeemable noncontrolling interests | (42,071 | ) | — | — | ||||||||
| Net loss attributable to NovaBridge | $ | (46,269 | ) | $ | (22,230 | ) | $ | (207,729 | ) | |||
| Comprehensive income (loss): | ||||||||||||
| Net loss | $ | (88,340 | ) | $ | (22,230 | ) | $ | (207,729 | ) | |||
| Unrealized gain (loss) on available-for-sale debt securities, net of tax | 11,580 | (8,168 | ) | — | ||||||||
| Reclassification of accumulated gains on available-for-sale debt securities to earnings |
(3,412 | ) | — | — | ||||||||
| Foreign currency translation adjustments, net of tax | (6 | ) | 1,781 | 5,605 | ||||||||
| Total other comprehensive loss | $ | (80,178 | ) | $ | (28,617 | ) | $ | (202,124 | ) | |||
| Comprehensive loss attributable to redeemable noncontrolling interests | (42,071 | ) | — | — | ||||||||
| Comprehensive loss attributable to NovaBridge | $ | (38,107 | ) | $ | (28,617 | ) | $ | (202,124 | ) | |||
| Weighted-average number of ordinary shares used in calculating net loss per share - basic and diluted |
220,258,932 | 186,728,372 | 191,423,850 | |||||||||
| Net loss per share from continuing operations attributable to NovaBridge - basic and diluted |
$ | (0.21 | ) | $ | (0.27 | ) | $ | (0.43 | ) | |||
| Net gain (loss) per share from discontinued operations - basic and diluted | $ | — | $ | 0.15 | $ | (0.66 | ) | |||||
| Net loss per share attributable to NovaBridge - basic and diluted | $ | (0.21 | ) | $ | (0.12 | ) | $ | (1.09 | ) | |||
| Net loss per ADS attributable to NovaBridge from continuing operations - basic and diluted |
$ | (0.48 | ) | $ | (0.61 | ) | $ | (0.99 | ) | |||
| Net gain (loss) per ADS from discontinued operations - basic and diluted | $ | — | $ | 0.34 | $ | (1.51 | ) | |||||
| Net loss per share attributable to NovaBridge - basic and diluted | $ | (0.48 | ) | $ | (0.27 | ) | $ | (2.50 | ) | |||
| Consolidated Statements of Cash Flows |
||||||||||||
| For the Years Ended |
||||||||||||
| (All amounts in thousands, unless otherwise noted) |
||||||||||||
| Year Ended |
||||||||||||
| 2025 |
2024 |
2023 |
||||||||||
| Cash flows from operating activities | ||||||||||||
| Net loss | $ | (88,340 | ) | $ | (22,230 | ) | $ | (207,729 | ) | |||
| Less: net gain (loss) from discontinued operations | — | 27,466 | (125,512 | ) | ||||||||
| Net loss from continuing operations | (88,340 | ) | (49,696 | ) | (82,217 | ) | ||||||
| Adjustments to reconcile net loss to net cash used in operating activities from continuing operations |
||||||||||||
| Share-based compensation | 5,974 | (1,949 | ) | 10,239 | ||||||||
| Change in fair value and extinguishment of put right liabilities | — | (13,852 | ) | 1,118 | ||||||||
| Equity in loss of affiliates | — | 1,038 | 11,404 | |||||||||
| Depreciation of property, equipment and software | 68 | 261 | 475 | |||||||||
| Impairment of goodwill | — | — | 23,041 | |||||||||
| Settlement of TJ Biopharma repurchase obligations | — | 12,388 | — | |||||||||
| Amortization of right-of-use assets | 788 | 717 | 586 | |||||||||
| Impairment of fixed assets | — | 1,246 | — | |||||||||
| (Gain) loss on disposal of property and equipment | 16 | (11 | ) | — | ||||||||
| Change in fair value of short-term and other investments | — | — | (221 | ) | ||||||||
| Fair value of acquired IPR&D asset expensed to R&D costs, net cash paid | 42,071 | — | — | |||||||||
| Recognition of accumulated gain associated with available-for-sale debt securities |
(3,412 | ) | — | — | ||||||||
| Change in fair value of equity securities | 5,164 | — | — | |||||||||
| Changes in operating assets and liabilities | ||||||||||||
| Prepayments and other receivables | (703 | ) | (1,904 | ) | 28 | |||||||
| Accruals and other payables | 18,081 | (213 | ) | (35,681 | ) | |||||||
| Other non-current liabilities | 512 | (106 | ) | (894 | ) | |||||||
| Operating lease liability, net | (816 | ) | (588 | ) | (575 | ) | ||||||
| Net cash used in operating activities from continuing operations | (20,597 | ) | (52,669 | ) | (72,697 | ) | ||||||
| Cash flows from investing activities | ||||||||||||
| Proceeds from disposal of short-term and other investments | 154,885 | 109,834 | 85,000 | |||||||||
| Purchase of short-term and other investments | (49,960 | ) | (194,748 | ) | (100,000 | ) | ||||||
| Purchase of available-for-sale debt securities | — | (51,115 | ) | — | ||||||||
| Purchase of property, equipment and software | (7 | ) | (48 | ) | (164 | ) | ||||||
| Proceeds from disposal of property and equipment | 47 | 62 | — | |||||||||
| Net cash generated from (used in) investing activities from continuing operations |
104,965 | (136,015 | ) | (15,164 | ) | |||||||
| Cash flows from financing activities | ||||||||||||
| Proceeds from underwritten offering, net | 61,714 | — | — | |||||||||
| Payments of deferred offering costs | (4,189 | ) | — | — | ||||||||
| Payment for stock repurchases | — | (335 | ) | (8,644 | ) | |||||||
| Proceeds from exercise of stock options | 200 | — | 407 | |||||||||
| Net cash generated from (used in) financing activities from continuing operations |
$ | 57,725 | $ | (335 | ) | $ | (8,237 | ) | ||||
| Consolidated Statements of Cash Flows (Continued) | ||||||||||||
| For the Years Ended |
||||||||||||
| (All amounts in thousands, unless otherwise noted) | ||||||||||||
| Year Ended |
||||||||||||
| 2025 | 2024 | 2023 | ||||||||||
| Discontinued operations: | ||||||||||||
| Net cash used in operating activities | $ | — | $ | (27,498 | ) | $ | (109,791 | ) | ||||
| Net cash (used in) generated from investing activities | — | (22,289 | ) | 26,077 | ||||||||
| Net cash (used in) generated from financing activities | — | (4,171 | ) | 9,911 | ||||||||
| Net cash used in discontinued operations | — | (53,958 | ) | (73,803 | ) | |||||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 276 | 573 | 5,197 | |||||||||
| Net increase (decrease) in cash and cash equivalents | 142,369 | (242,404 | ) | (164,704 | ) | |||||||
| Cash and cash equivalents, beginning of year | 68,263 | 310,667 | 475,371 | |||||||||
| Cash and cash equivalents, end of year | $ | 210,632 | $ | 68,263 | $ | 310,667 | ||||||
| Additional ASC 842 supplemental disclosures | ||||||||||||
| Cash paid for fixed operating lease costs included in the measurement of lease | ||||||||||||
| obligations in operating activities | $ | 1,011 | $ | 805 | $ | 739 | ||||||
| Right-of-use assets obtained in exchange for operating lease obligations | $ | — | $ | 282 | $ | 1,426 | ||||||
| Non-cash activities | ||||||||||||
| Accrued acquisition costs and deferred payments associated with |
||||||||||||
| acquisition | $ | 2,375 | $ | — | $ | — | ||||||
| Unrealized gain (loss) on available-for-sale debt securities | $ | 11,580 | $ | (8,168 | ) | $ | — | |||||
| The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets: | ||||||||||||
| Cash and cash equivalents | $ | 210,632 | $ | 68,263 | $ | 291,506 | ||||||
| Cash and cash equivalents in current assets of discontinued operations | — | — | 10,843 | |||||||||
| Restricted cash in non-current assets of discontinued operations | — | — | 8,318 | |||||||||
| Total cash and cash equivalents and restricted cash | $ | 210,632 | $ | 68,263 | $ | 310,667 | ||||||
| Consolidated Statements of Changes in Shareholders’ Equity |
||||||||||||||||||||||||||||||||
| For the Years Ended |
||||||||||||||||||||||||||||||||
| (All amounts in thousands, except for share data, unless otherwise noted) |
||||||||||||||||||||||||||||||||
| Accumulated | ||||||||||||||||||||||||||||||||
| Ordinary share | other | |||||||||||||||||||||||||||||||
| ( |
Additional | comprehensive | Total | |||||||||||||||||||||||||||||
| Number of | Number of | paid-in | income | Accumulated | shareholders’ | |||||||||||||||||||||||||||
| shares | Amount | shares | Amount | capital | (loss) | deficit | equity | |||||||||||||||||||||||||
| Balance as of |
192,532,460 | $ | 19 | (1,652,541 | ) | $ | (3,006 | ) | $ | 1,442,714 | $ | 34,166 | $ | (1,056,080 | ) | $ | 417,813 | |||||||||||||||
| Foreign currency translation adjustments | — | — | — | — | — | 5,605 | — | 5,605 | ||||||||||||||||||||||||
| Net loss | — | — | — | — | — | — | (207,729 | ) | (207,729 | ) | ||||||||||||||||||||||
| Share-based compensation | — | — | — | — | 27,348 | — | — | 27,348 | ||||||||||||||||||||||||
| Exercise of stock options | 280,568 | — | 126,874 | 120 | 287 | — | — | 407 | ||||||||||||||||||||||||
| Issuance of ordinary shares for RSUs | 1,260,701 | — | 3,722,394 | 3,523 | (3,523 | ) | — | — | — | |||||||||||||||||||||||
| Repurchase of shares | — | — | (10,656,794 | ) | (8,644 | ) | — | — | — | (8,644 | ) | |||||||||||||||||||||
| Proportionate share of share-based compensation expenses recorded in an equity method affiliate |
— | — | — | 7,784 | — | — | 7,784 | |||||||||||||||||||||||||
| Balance as of |
194,073,729 | $ | 19 | (8,460,067 | ) | $ | (8,007 | ) | $ | 1,474,610 | $ | 39,771 | $ | (1,263,809 | ) | $ | 242,584 | |||||||||||||||
| Balance as of |
194,073,729 | $ | 19 | (8,460,067 | ) | $ | (8,007 | ) | $ | 1,474,610 | $ | 39,771 | $ | (1,263,809 | ) | $ | 242,584 | |||||||||||||||
| Foreign currency translation adjustments | — | — | — | — | — | 1,781 | — | 1,781 | ||||||||||||||||||||||||
| Net loss | — | — | — | — | — | — | (22,230 | ) | (22,230 | ) | ||||||||||||||||||||||
| Unrealized loss on available-for-sale debt securities |
— | — | — | — | — | (8,168 | ) | — | (8,168 | ) | ||||||||||||||||||||||
| Share-based compensation | — | — | — | — | (13,510 | ) | — | — | (13,510 | ) | ||||||||||||||||||||||
| Issuance of ordinary shares for RSUs | — | — | 2,252,047 | 2,117 | (2,117 | ) | — | — | — | |||||||||||||||||||||||
| Repurchase of shares | — | — | (413,214 | ) | (335 | ) | — | — | — | (335 | ) | |||||||||||||||||||||
| Proportionate share of share-based compensation expenses recorded in an equity method affiliate |
— | — | — | — | 1,038 | — | — | 1,038 | ||||||||||||||||||||||||
| Balance as of |
194,073,729 | $ | 19 | (6,621,234 | ) | $ | (6,225 | ) | $ | 1,460,021 | $ | 33,384 | $ | (1,286,039 | ) | $ | 201,160 | |||||||||||||||
| Balance as of |
194,073,729 | $ | 19 | (6,621,234 | ) | $ | (6,225 | ) | $ | 1,460,021 | $ | 33,384 | $ | (1,286,039 | ) | $ | 201,160 | |||||||||||||||
| Foreign currency translation adjustments | — | — | — | — | — | (6 | ) | — | (6 | ) | ||||||||||||||||||||||
| Net loss | — | — | — | — | — | — | (46,269 | ) | (46,269 | ) | ||||||||||||||||||||||
| Unrealized gain on available-for-sale debt securities |
— | — | — | — | — | 11,580 | — | 11,580 | ||||||||||||||||||||||||
| Reclassification of accumulated gains on available-for-sale debt securities to earnings |
— | — | — | — | — | (3,412 | ) | — | (3,412 | ) | ||||||||||||||||||||||
| Share-based compensation | — | — | — | — | 5,974 | — | — | 5,974 | ||||||||||||||||||||||||
| Issuance of ordinary shares in underwritten offering, net of expenses |
76,666,659 | 8 | — | — | 61,706 | — | — | 61,714 | ||||||||||||||||||||||||
| Exercise of stock options | — | — | 347,843 | 327 | (127 | ) | — | — | 200 | |||||||||||||||||||||||
| Issuance of ordinary shares for RSUs | — | — | 910,894 | 856 | (856 | ) | — | — | — | |||||||||||||||||||||||
| Balance as of |
270,740,388 | $ | 27 | (5,362,497 | ) | $ | (5,042 | ) | $ | 1,526,718 | $ | 41,546 | $ | (1,332,308 | ) | $ | 230,941 | |||||||||||||||
Source: NovaBridge Biosciences